scholarly article | Q13442814 |
P50 | author | Mark Lathrop | Q6768494 |
Peter McGuffin | Q7175787 | ||
Pierandrea Muglia | Q89919709 | ||
Piotr M Czerski | Q90589643 | ||
Daniel Souery | Q92151258 | ||
Nader Perroud | Q103779206 | ||
Borut Jerman | Q114301483 | ||
Anna Placentino | Q114432657 | ||
Astrid Zobel | Q114561208 | ||
Katrina Pirlo | Q125264192 | ||
Cathryn Lewis | Q16731445 | ||
Marcella Rietschel | Q20742720 | ||
Ian W. Craig | Q30506522 | ||
Michael R. Barnes | Q37650961 | ||
Katherine J. Aitchison | Q37828818 | ||
Ole Mors | Q41638422 | ||
Rudolf Uher | Q43273047 | ||
Sarah Cohen-Woods | Q44547557 | ||
Neven Henigsberg | Q45729464 | ||
Gerome Breen | Q47502400 | ||
Erik Roj Larsen | Q56380953 | ||
Amy Butler | Q58098008 | ||
Thomas G. Schulze | Q61995101 | ||
Joanna Twarowska-Hauser | Q89213422 | ||
P2093 | author name string | Anne Farmer | |
Wolfgang Maier | |||
Tina Zagar | |||
Mandy Y M Ng | |||
P2860 | cites work | Conduct disorder and ADHD: evaluation of conduct problems as a categorical and quantitative trait in the international multicentre ADHD genetics study | Q28943364 |
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 555-564 | |
P577 | publication date | 2010-04-01 | |
P1433 | published in | American Journal of Psychiatry | Q1935368 |
P1476 | title | Genome-wide pharmacogenetics of antidepressant response in the GENDEP project | |
P478 | volume | 167 |
Q36541051 | A dialogue between the immune system and brain, spoken in the language of serotonin |
Q92384370 | A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression |
Q64281271 | A genome-wide association meta-analysis of prognostic outcomes following cognitive behavioural therapy in individuals with anxiety and depressive disorders |
Q34347951 | A genome-wide association study of a sustained pattern of antidepressant response |
Q28597255 | A genome-wide association study of antidepressant response in Koreans |
Q89747545 | A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping |
Q39021015 | ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis |
Q48468840 | ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway. |
Q37388467 | Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-β mRNA Levels Accurately Predict Treatment Response in Depressed Patients. |
Q48377309 | An association and haplotype analysis of porcine maternal infanticide: a model for human puerperal psychosis? |
Q31130220 | Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response |
Q48617573 | Analysis of 34 candidate genes in bupropion and placebo remission. |
Q91635696 | Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder |
Q54966148 | Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables. |
Q33930731 | Antidepressant treatment response is modulated by genetic and environmental factors and their interactions |
Q37986775 | Assessing gene-gene interactions in pharmacogenomics |
Q38540142 | BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients. |
Q38171656 | Behavior genetics: past, present, future |
Q47659995 | Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. |
Q38269353 | Biomarker studies and the future of personalized treatment for depression |
Q47671635 | Biomarkers for Major Depressive Disorder: Economic Considerations |
Q36593269 | Biomarkers predicting treatment outcome in depression: what is clinically significant? |
Q34247513 | Biomarkers to predict antidepressant response |
Q47555879 | Blood-based biomarkers predicting response to antidepressants. |
Q47652242 | Blue Genes? Understanding and Mitigating Negative Consequences of Personalized Information about Genetic Risk for Depression |
Q36539999 | Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. |
Q24202141 | Citalopram versus other anti-depressive agents for depression |
Q27001088 | Cognitive mechanisms of treatment in depression |
Q47239298 | Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity |
Q38823641 | Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response |
Q34292369 | Convergent evidence from mouse and human studies suggests the involvement of zinc finger protein 326 gene in antidepressant treatment response |
Q48367416 | Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. |
Q34975631 | Copy number variants in pharmacogenetic genes |
Q34708116 | Cytokine variations and mood disorders: influence of social stressors and social support |
Q37201357 | DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP |
Q38070163 | Do we need pharmacogenetics to personalize antidepressant therapy? |
Q102369303 | ERICH3: vesicular association and antidepressant treatment response |
Q38211978 | Early switching strategies in antidepressant non-responders: current evidence and future research directions. |
Q46011308 | Effects of antidepressant drug exposure on gene expression in the developing cerebral cortex. |
Q51690060 | Epidemiology, epigenetics and the 'Gloomy Prospect': embracing randomness in population health research and practice. |
Q34426216 | Epigenetic alterations in depression and antidepressant treatment |
Q38504484 | Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: environmental challenge |
Q38504481 | Escitalopram modulates neuron-remodelling proteins in a rat gene-environment interaction model of depression as revealed by proteomics. Part I: genetic background |
Q38394152 | Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design |
Q24632901 | Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains |
Q26991710 | Exploring the effects of polymorphisms on cis-regulatory signal transduction response |
Q27015830 | From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment |
Q38154917 | Gene expression: biomarker of antidepressant therapy? |
Q38067101 | Gene × environment interactions in the prediction of response to antidepressant treatment |
Q37971344 | Gene-environment interaction in major depression and antidepressant treatment response |
Q58786918 | Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP) |
Q37483043 | Genetic Contributions of Inflammation to Depression |
Q45729383 | Genetic differences in cytochrome P450 enzymes and antidepressant treatment response |
Q48372657 | Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. |
Q28484419 | Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis |
Q35023117 | Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: a genome-wide association and polygenic scoring study |
Q44478530 | Genetic susceptibility for bipolar disorder and response to antidepressants in major depressive disorder |
Q35653883 | Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs |
Q48070708 | Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder |
Q47213690 | Genetics and psychiatry: a proposal for the application of the precautionary principle |
Q38410122 | Genetics in child and adolescent psychiatry: methodological advances and conceptual issues |
Q37603806 | Genome-wide Association for Major Depression Through Age at Onset Stratification: Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium |
Q36973699 | Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response |
Q38444447 | Genome-wide association studies in pharmacogenomics of antidepressants |
Q101237251 | Genome-wide association studies of antidepressant class response and treatment-resistant depression |
Q35074796 | Genome-wide association studies of antidepressant outcome: a brief review |
Q35993192 | Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway |
Q64444709 | Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP |
Q21134099 | Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13) |
Q49024786 | Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. |
Q37223300 | Genome-wide association study of response to cognitive-behavioural therapy in children with anxiety disorders. |
Q39589817 | Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker |
Q39293823 | Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers |
Q37045112 | Genome-wide scan of job-related exhaustion with three replication studies implicate a susceptibility variant at the UST gene locus |
Q45729483 | Genomewide interaction and enrichment analysis on antidepressant response |
Q34555598 | Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics |
Q35592683 | High dimensional endophenotype ranking in the search for major depression risk genes |
Q33697992 | Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression |
Q40504312 | IL6-174G > C genetic polymorphism influences antidepressant treatment outcome |
Q37200660 | Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models |
Q37223293 | Immune signatures and disorder-specific patterns in a cross-disorder gene expression analysis |
Q38044323 | Implications of the use of genetic tests in psychiatry, with a focus on major depressive disorder: a review |
Q50786215 | Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. |
Q37961088 | Integrative genomics strategies to elucidate the complexity of drug response |
Q35150183 | Investigation of blood mRNA biomarkers for suicidality in an independent sample |
Q34731202 | Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates |
Q37182897 | Machine learning, statistical learning and the future of biological research in psychiatry |
Q36096664 | Major depressive disorder: new clinical, neurobiological, and treatment perspectives |
Q47118154 | MicroRNA-Mediated Regulation of ITGB3 and CHL1 Is Implicated in SSRI Action |
Q38694557 | Neurobehavioral comorbidities of epilepsy: Role of inflammation. |
Q47436767 | New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. |
Q48102611 | No support for replication of the genetic variants identified by a recent mega-analysis of the treatment response to antidepressants. |
Q38317241 | Novel investigational drugs targeting IL-6 signaling for the treatment of depression |
Q43568484 | Overlapping effects of genetic variation and epigenetics on drug response: challenges of pharmacoepigenomics |
Q38657429 | Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks |
Q92710468 | Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis |
Q37789098 | Personalized medicine for depression: can we match patients with treatments? |
Q38756015 | Personalized medicine: Genetic risk prediction of drug response |
Q35952370 | PharmGKB summary: citalopram pharmacokinetics pathway |
Q42926677 | Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population |
Q92907278 | Pharmacogenetics and Depression: A Critical Perspective |
Q37956206 | Pharmacogenetics in psychiatry: translating research into clinical practice. |
Q38121519 | Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research |
Q37989490 | Pharmacogenetics of antidepressant drugs: current clinical practice and future directions |
Q34155796 | Pharmacogenetics of antidepressant response |
Q35026088 | Pharmacogenetics of antidepressants |
Q38484370 | Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications |
Q38139479 | Pharmacogenetics of mood disorders: what clinicians need to know |
Q37658586 | Pharmacogenomics and patient care: one size does not fit all. |
Q27001573 | Pharmacogenomics discovery and implementation in genome-wide association studies era |
Q42361493 | Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry |
Q37614819 | Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics |
Q89329295 | Pharmacogenomics: A focus on antidepressants and atypical antipsychotics |
Q38099042 | Pharmacological management of unipolar depression |
Q35032056 | Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. |
Q47624828 | Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains |
Q36583679 | Polygenic interactions with environmental adversity in the aetiology of major depressive disorder. |
Q57303389 | Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts |
Q38258243 | Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. |
Q48682021 | Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder. |
Q38814860 | Precision medicine for psychopharmacology: a general introduction |
Q28710054 | Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial |
Q30249569 | Progress and prospects in pharmacogenetics of antidepressant drugs |
Q47666907 | Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years |
Q45390458 | Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. |
Q26825110 | Proteoglycans and neuronal migration in the cerebral cortex during development and disease |
Q35117863 | Putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients |
Q34131354 | Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice |
Q34459775 | Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels |
Q34343309 | Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis |
Q38845473 | Separate and combined effects of genetic variants and pre-treatment whole blood gene expression on response to exposure-based cognitive behavioural therapy for anxiety disorders |
Q34473840 | Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders |
Q35755912 | Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. |
Q45022135 | Summaries of plenary, symposia, and oral sessions at the XXII World Congress of Psychiatric Genetics, Copenhagen, Denmark, 12-16 October 2014. |
Q64249357 | Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk |
Q47912001 | Systems genetics analysis of pharmacogenomics variation during antidepressant treatment. |
Q37213132 | TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics |
Q89747287 | Targeted exome sequencing identifies five novel loci at genome-wide significance for modulating antidepressant response in patients with major depressive disorder |
Q38189135 | Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? |
Q37072176 | Testing a machine-learning algorithm to predict the persistence and severity of major depressive disorder from baseline self-reports. |
Q35715254 | The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. |
Q55113792 | The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response Study: Design and Methodology. |
Q89510117 | The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review |
Q38453405 | The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study |
Q37914871 | The genetic blueprint of major depressive disorder: contributions of imaging genetics studies |
Q38187699 | The inflammatory cytokines: molecular biomarkers for major depressive disorder? |
Q58864945 | The norepinephrine transporter gene is a candidate gene for panic disorder |
Q36618462 | Therapygenetics: Using genetic markers to predict response to psychological treatment for mood and anxiety disorders |
Q38956222 | Toward a Global Roadmap for Precision Medicine in Psychiatry: Challenges and Opportunities. |
Q92431605 | Treatment response classes in major depressive disorder identified by model-based clustering and validated by clinical prediction models |
Q34424865 | Understanding the pharmacogenetics of selective serotonin reuptake inhibitors |
Q47668646 | Unpacking Major Depressive Disorder: From Classification to Treatment Selection |
Q37446677 | Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder |
Q37016538 | Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients |
Q38154916 | Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment. |
Q37880738 | What little we know about tailoring depression treatment for individual patients |
Q47830777 | Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. |
Q49567721 | [Pharmacogenetics in psychiatry: state of the art]. |
Search more.